ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2709 • 2013 ACR/ARHP Annual Meeting

    Secreted Frizzled-Related Protein 4 Can Be Induced By Transforming Growth Factor-β, Is Regulated By Caveolin-1 and Can Induce Non-Canonical Wnt Signaling In Fibroblasts

    Justin Gillespie1, Giuseppina Abignano1, Michael McDermott1, Paul Emery1 and Francesco Del Galdo2, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: Systemic Sclerosis (SSc) is a heterogeneous disease characterized by autoimmune activation, fibroproliferative vasculopathy, and tissue fibrosis of skin and multiple internal organs. Several studies…
  • Abstract Number: 2710 • 2013 ACR/ARHP Annual Meeting

    Deficiency Of The Protein Kinase Ataxia Telangiectasia Mutated Accelerates T Cell Aging In Rheumatoid Arthritis

    Zhen Yang1, Hiroshi Fujii2, Eric L. Matteson3, Jorg J. Goronzy1 and Cornelia M. Weyand4, 1Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 2Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, 3Rheumatology, Mayo Clinic, Rochester, MN, 4Medicine, Stanford University School of Medicine, Stanford, CA

    Background/Purpose: T lymphocytes hold a pinnacle position in the pathogenesis of rheumatoid arthritis (RA) and through their longevity contribute to disease chronicity. The protein kinase…
  • Abstract Number: 2711 • 2013 ACR/ARHP Annual Meeting

    Self-Specific Polyclonal CD4 T Cells Enter a FR4hi CD73hi Anergic State To Prevent Immunopathology and Serve As a Reservoir For The Differentiation Of Protective Foxp3+ Tregs

    Lokesh Kalekar1 and Daniel L. Mueller2, 1University of Minnesota Medical School, Minneapolis, MN, 2Medicine/Rheumatic and Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN

    Background/Purpose: Clonal anergy has been proposed as a mechanism to allow for peripheral recognition of self antigens, without the consequence of immunopathology. Model systems have…
  • Abstract Number: 2712 • 2013 ACR/ARHP Annual Meeting

    Increased Soluble PD-1: A Link Between Generation Of Immunological Memory and Risk Of Disease Flare In Early RA

    Stinne Greisen1, Tue W. Kragstrup2, Kristian Stengaard-Pedersen3, Merete Lund Hetland4, Kim Hørslev-Petersen5, Malene Hvid6 and Bent Deleuran2, 1Dept of Biomedicine, Aarhus University, Aarhus, Denmark, 2Department of Biomedicine, Aarhus University, Aarhus, Denmark, 3Arhus University Hospital, Aarhus, Denmark, 4Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, 5Institute of Regional Health Services Research, University of Southern Denmark, Graasten, Denmark, 6Dept. of Clinical Medicine, Aarhus University, Aarhus, Denmark

    Background/Purpose: Disturbances in the regulatory mechanisms of the immune system play a major role in rheumatoid arthritis (RA). Programmed Death 1 (PD-1) on lymphocytes negatively…
  • Abstract Number: 2713 • 2013 ACR/ARHP Annual Meeting

    IL-21 Inhibited Follicular Regulatory T Cells To Promote Autoreactive Germinal Center Development In Autoimmune BXD2 Mice

    Yanna Ding1, Hui-Chen Hsu2,3, Jun Li4, PingAr Yang4, Qi Wu4, Allan J. Zajac5 and John D. Mountz3,6, 1University of Alabama at Birmingham, Birmingham, AL, 2Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Birmingham VA Medical Center, Birmingham, AL, 4Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 5Microbiology, University of Alabama at Birmingham, Birmingham, AL, 6Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Follicular T helper (Tfh) cells have been correlated with germinal center (GC) formation, autoantibody production and disease severity in human systemic lupus erythematosus (SLE).…
  • Abstract Number: 2714 • 2013 ACR/ARHP Annual Meeting

    Commensal Intestinal Microbiota Drives Spontaneous Interleukin-1- and T Helper 17-Mediated Arthritis In Mice

    Shahla Abdollahi-Roodsaz1, Rebecca Rogier2, Tom Ederveen2, Harm Wopereis3, Raish Oozeer3, Marije I. Koenders2 and Wim B. van den Berg1, 1Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, 3Danone Research, Wageningen, Netherlands

    Background/Purpose: Altered composition of intestinal microbiota in recent-onset rheumatoid arthritis (RA) and possible efficacy of oral antibiotics suggest a role of intestinal microbiota in RA.…
  • Abstract Number: 2677 • 2013 ACR/ARHP Annual Meeting

    Disease Progression Into Adulthood In Patients With Juvenile Idiopathic Arthritis – a Longitudinal 30 Year Follow-Up Study

    Anne Marit Selvaag, Hanne Aulie, Vibke Lilleby and Berit Flatø, Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway

    Background/Purpose: The aim of the study was to assess disease activity and health status in a previously studied cohort of patients with juvenile idiopathic arthritis…
  • Abstract Number: 2675 • 2013 ACR/ARHP Annual Meeting

    Phase 2 Trial On Triptorelin For Ovary Protection In Childhood-Onset Systemic Lupus Erythematosus

    Rina Mina1, Andreas Reiff2, Clovis A. Silva3, Patricia Vega Fernandez4, Gloria C. Higgins5, Lisa F. Imundo6, Marisa S. Klein-Gitelman7, Calvin Williams8, Carol A. Wallace9, Nadia E. Aikawa10, Shannen L. Nelson11, Jun Ying12, Susan R. Rose13 and Hermine Brunner14, 1Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, 3Children's Institute, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 4Cincinnati Children's Hospital Medica Center, CINCINNATI, OH, 5Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, 6Pediatric and Adult Rheumatology Columbia University Medical Center, New York, NY, 7Division of Rheumatology, Children's Memorial Hospital, Chicago, IL, 8Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, 9University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, 10Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 11Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 12Medicine-Internal Medicine-General Medicine, University of Cincinnati, Cincinnati, OH, 13Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 14PRCSG, Cincinnati, OH

    Background/Purpose: Gonadotoxicity is a known side effect of cyclophosphamide (CYC) therapy in childhood-onset systemic lupus erythematosus (cSLE).  Gonadotropin releasing hormone (GnRH) agonists, such as triptorelin,…
  • Abstract Number: 2676 • 2013 ACR/ARHP Annual Meeting

    Increased Pulse Wave Velocity In Juvenile Idiopathic Arthritis Patients Compared To Controls From The General Population

    Hanne A. Aulie1, Anne Marit Selvaag1, Vibke Lilleby1, Oyvind Molberg1, Anders Hartmann2, Hallvard Holdaas2 and Berit Flato1, 1Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 2Department of Nephrology (and specialised Endocrinology), Oslo University Hospital, Rikshospitalet, Oslo, Norway

    Background/Purpose: The aim of this study was to compare markers of subclinical cardiovascular disease (CVD) in adults with juvenile idiopathic arthritis (JIA) and controls, and…
  • Abstract Number: 2678 • 2013 ACR/ARHP Annual Meeting

    Medically Significant Infections Are Increased In Patients With Juvenile Idiopathic Arthritis Treated With Etanercept. Results From The British Society For Paediatric and Adolescent Rheumatology Etanercept Cohort Study

    Rebecca Davies1, Taunton R. Southwood2, Lianne Kearsley-Fleet1, Mark Lunt3, Kimme L. Hyrich4 and on Behalf Of The BSPAR Etanercept Cohort Study5, 1Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 2Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, 3Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, 4Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 5Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom

    Background/Purpose: The association between anti-TNF therapy and increased rate of infection are widely documented in adults with rheumatoid arthritis. Findings in children with juvenile idiopathic…
  • Abstract Number: 2679 • 2013 ACR/ARHP Annual Meeting

    Incidence Rates Of Serious Infections and Infection Subtypes Among Pediatric Systemic Lupus Erythematosus Patients Enrolled In Medicaid, According To Medication Use

    Linda T. Hiraki1, Candace H. Feldman2, Mary Beth Son3, Jessica M. Franklin4, Michael A. Fischer4, Daniel H. Solomon5, Seoyoung C. Kim6, Wolfgang C. Winkelmayer7 and Karen H. Costenbader2, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Division of Immunology, Boston Children's Hospital, Boston, MA, 4Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 5Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, 6Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 7Division of Nephrology, Stanford University School of Medicine, Stanford, CA

    Incidence Rates Of Serious Infections and Infection Subtypes Among Pediatric Systemic Lupus Erythematosus Patients Enrolled In Medicaid, According To Medication UseBackground/Purpose: We investigated incidence rates…
  • Abstract Number: 2680 • 2013 ACR/ARHP Annual Meeting

    Risk of Subsequent Infection among Rheumatoid Arthritis  Patients Using Biologics

    Huifeng Yun1, Fenglong Xie2, Elizabeth S. Delzell1, Lang Chen3, Emily Levitan1, James Lewis4, Kenneth G. Saag5, Timothy Beukelman6, Kevin L. Winthrop7, John Baddley8, Paul M. Muntner1 and Jeffrey R. Curtis3, 1Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 2Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 3Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4Medicine, University of Pennsylvania, Philadelphia, PA, 5Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, 6Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 7Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, 8Medicine, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Much has been written about infections associated with biologic agents in patients with rheumatoid arthritis (RA). However, less is known about the risk of…
  • Abstract Number: 2681 • 2013 ACR/ARHP Annual Meeting

    Reduced Fertility In Women With Rheumatoid Arthritis: Influence Of Disease Activity and Medication Use

    Jenny Brouwer1,2, Johanna MW Hazes1, Joop SE Laven2 and Radboud JEM Dolhain1, 1Rheumatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, 2Obstetrics & Gynaecology, division of Reproductive Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands

    Background/Purpose: Many female rheumatoid arthritis (RA) patients who try to conceive have a time to pregnancy (TTP) longer than 12 months.  During this period RA…
  • Abstract Number: 2682 • 2013 ACR/ARHP Annual Meeting

    Incidence Trends and Predictors Of Orthopedic Surgery In Patients With Rheumatoid Arthritis – Results From a Well Defined Population

    Korosh Hekmat1, Lennart Jacobsson2, Jan-Åke Nilsson3, Minna Willim4, Martin Englund5, Ingemar F. Petersson6 and Carl Turesson2, 1Department of Clinical Sciences, Section of Rheumatology, Malmö, Lund University, Malmö, Sweden, 2Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 3Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 4Department of Clinical Sciences Malmö, Section of Rheumatology, Lund University, Malmö, Sweden, 5Department of Orthopedics, Clinical Sciences Lund,, Lund University, Lund, Sweden, 6Musculoskeletal Scienes, Department of Orthopedics, Clinical Sciences, Lund, Sweden

    Background/Purpose:  Orthopedic surgery is used effectively in many patients with severe rheumatoid arthritis (RA). The aim of modern pharmacologic treatment is to prevent joint destruction…
  • Abstract Number: 2683 • 2013 ACR/ARHP Annual Meeting

    Application Of a Multi-Biomarker Disease Activity (Vectra® DA) Score For Assessing Rheumatoid Arthritis Patients With Fibromyalgia Or Low C-Reactive Protein

    Yvonne C. Lee1, James Hackett2, Claire Alexander3, Michelle A. Frits1, Christine K. Iannaccone1, Nancy A. Shadick4, Michael E. Weinblatt5, Oscar Segurado6 and Eric H. Sasso6, 1Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Hackett & Associates, Inc., San Diego, CA, 3Clinical Operations, Crescendo Bioscience Inc., South San Francisco, CA, 4Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA, 5Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA, 6Crescendo Bioscience Inc., South San Francisco, CA

    Background/Purpose: Clinical assessment of rheumatoid arthritis (RA) may be challenging if patients have fibromyalgia (FM) or if C-reactive protein (CRP) is low (£1 mg/dL). A…
  • « Previous Page
  • 1
  • …
  • 2070
  • 2071
  • 2072
  • 2073
  • 2074
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology